Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
2rZvHRGpLNCN8wsN
Listen
